2022 the Japanese Society of Medical Oncology Annual Meeting

Presentation information

Oral Session

[O13] Oral Session 13 Lung Cancer / Thoracic Cancer 3(Rare gene alterations)
【E】

Sat. Feb 19, 2022 8:20 AM - 9:50 AM Room 1 (Main Hall, 1F, Kyoto International Conference Center)

Chair:Satoshi Oizumi(Department of Respiratory Medicine, National Hospital Organization Hokkaido Cancer Center),Haruyasu Murakami(Chemotherapy Center/Division of Thoracic Oncology, Shizuoka Cancer Center)
Discussant:Takehito Shukuya(Department of Respiratory Medicine, Juntendo University)

[O13-6] Japanese Subgroup Analysis of Datopotamab Deruxtecan in NSCLC Cohort of TROPION-PanTumor01, a Phase 1 Study

Toshio Shimizu1, Satoru Kitazono2, Edward B Garon3, Melissa L Johnson4, Aaron Lisberg3, Alexander Spira5, Noboru Yamamoto1, Rebecca S Heist6, Jacob M Sands7, Funda Meric-Bernstam8, Yoshitaka Zenke9, Noriko Yanagitani2, Jonathan Greenberg10, Fumiaki Kobayashi11, Yui Kawasaki11, Kiyotaka Yoh9 (1.National Cancer Center Hospital, Tokyo, Japan, 2.The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, 3.David Geffen School of Medicine at UCLA, Los Angeles, CA, USA, 4.Sarah Cannon Research Institute, Tennessee Oncology, PLLC, One Oncology, Nashville, TN, USA, 5.Virginia Cancer Specialists and US Oncology Research, Fairfax, VA, USA, 6.Massachusetts General Hospital, Boston, MA, USA, 7.Dana-Farber Cancer Institute, Boston, MA, USA, 8.The University of Texas MD Anderson Cancer Center, Houston, TX, USA, 9.National Cancer Center Hospital East, Chiba, Japan, 10.Daiichi Sankyo, Inc, Basking Ridge, NJ, USA, 11.Daiichi Sankyo Co, Ltd, Tokyo, Japan)

Abstract password authentication.
The password can be found on page 27 of the program book.

Password